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The aim of this study was to evaluate the efficacy of high dose genistein aglycone
in Sanfilippo syndrome (mucopolysaccharidosis type III). High doses of genistein
aglycone have been shown to correct neuropathology and hyperactive behaviour
in mice, but efficacy in humans is uncertain. This was a single centre, double-
blinded, randomised, placebo-controlled study with open-label extension phase.
Randomised participants received either 160 mg/kg/day genistein aglycone or pla-
cebo for 12 months; subsequently all participants received genistein for 12 months.
The primary outcome measure was the change in heparan sulfate concentration in
cerebrospinal fluid (CSF), with secondary outcome measures including heparan
sulfate in plasma and urine, total glycosaminoglycans in urine, cognitive and adap-
tive behaviour scores, quality of life measures and actigraphy. Twenty-one partici-
pants were randomised and 20 completed the placebo-controlled phase. After
12 months of treatment, the CSF heparan sulfate concentration was 5.5% lower in
the genistein group (adjusted for baseline values), but this was not statistically sig-
nificant (P = .26), and CSF heparan sulfate increased in both groups during the
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open-label extension phase. Reduction of urinary glycosaminoglycans was signifi-
cantly greater in the genistein group (32.1% lower than placebo after 12 months,
P= .0495). Other biochemical and clinical parameters showed no significant differ-
ences between groups. High dose genistein aglycone (160 mg/kg/day) was not
associated with clinically meaningful reductions in CSF heparan sulfate and no
evidence of clinical efficacy was detected. However, there was a statistically signifi-
cant reduction in urine glycosaminoglycans. These data do not support the use of
genistein aglycone therapy in mucopolysaccharidosis type III. High dose genistein
aglycone does not lead to clinically meaningful reductions in biomarkers or
improvement in neuropsychological outcomes in mucopolysaccharidosis type III.
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1 | INTRODUCTION
Mucopolysaccharidosis type III (MPS III, Sanfilippo
syndrome), is a rare lysosomal storage disease with four sub-
types (A, B, C and D), each caused by the deficiency of a dif-
ferent enzyme involved in the degradation of the
glycosaminoglycan (GAG) heparan sulfate (HS). The clinical
picture is dominated by progressive central nervous system
disease.1 Early mild developmental delay is followed by the
development of a severe behavioural disorder from 3 to
5 years of age (hyperactivity, aggressive behaviour, sleep dis-
turbance), and the beginning of progressive cognitive decline.
From around 10 years of age, motor function, feeding and
swallowing progressively deteriorate, and death often occurs
by the second decade, though some very attenuated patients
do exist.2,3 The subtypes are clinically similar, though disease
progression may be slower in MPS IIIC.4,5 No disease-
modifying therapy is yet available, though several gene ther-
apy strategies are in development, and some are in clinical
trials.6,7 Enzyme replacement therapy (ERT) approaches
have not shown efficacy.8,9 Substrate reduction therapy
(SRT) is an alternative approach in which treatment aims to
reduce endogenous synthesis of macromolecules. SRT has
been approved for Niemann-Pick type C (miglustat)10 and
Gaucher disease (miglustat and eliglustat).11,12
Genistein (40,5,7-trihydroxyisoflavone) is an isoflavone
with weak phytoestrogen properties that is abundant in soy
foods, predominantly in glycoside form. The biologically
active aglycone can be purified or synthesised chemically.
Genistein has several different mechanisms of action,13,14
but three in particular make it a candidate SRT for MPS III.
Firstly, genistein may reduce endogenous GAG synthesis by
inhibition of the epidermal growth factor (EGF) receptor
tyrosine kinase.15,16 Secondly, it may enhance lysosomal
degradation of GAGs through its action on transcription
factor EB.17,18 Thirdly, it has the potential to treat central
nervous system (CNS) disease, as a small proportion has
been shown to cross the blood-brain barrier in rats.19
Pre-clinical studies of genistein in MPS IIIB mice found
reductions in peripheral and brain GAG storage, and in
neuroinflammation.20,21 High-dose genistein aglycone
(160 mg/kg/day) also corrected abnormal hyperactive
behaviour.21 Results of clinical studies in MPS III are vari-
able. In small open-label studies of genistein, some found
reduced urinary GAG (uGAG) excretion but no significant
behavioural changes,22,23 while another found no reduction
in uGAG and deterioration of disability scores.24 In the only
double-blinded, placebo-controlled trial to date, de Ruijter
et al found reductions in uGAG and plasma HS, though no
behavioural changes were observed.25 However, these stud-
ies all used low doses of soy-derived genistein (5-10 mg/kg/
day), whereas only high doses of genistein aglycone
(160 mg/kg/day) corrected behaviour in mice.21 Doses of up
to 150 mg/kg/day of genistein aglycone have been shown to
be safely tolerated in patients with MPS II and MPS III, with
only minor adverse effects in a small number of partici-
pants.26 However, this study did not formally assess efficacy.
Many families continue to use genistein, often at consider-
able expense, without clear evidence of efficacy. In this
study, we investigate the efficacy and long-term safety of
high dose genistein aglycone in patients with MPS III.
2 | METHODS
2.1 | Standard protocol approvals,
registrations, and patient consents
The GENiSIS2013 study (High Dose Genistein in
Sanfilippo Syndrome) took place from August 2014 to
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June 2018 at Manchester University Hospitals Founda-
tion Trust. The study was registered in clinical trials data-
base EudraCT: 2013-001479-18. Ethical approval was
given by the Office for Research Ethics Committees,
Northern Ireland (ORECNI) (REC 14/NI/0006). Informed
consent was obtained for all participants and the study
was conducted in accordance with the principles set out in
the WMA Declaration of Helsinki.
2.2 | Clinical trial design
This was a single-centre, randomised, double-blinded,
placebo-controlled trial with open-label extension. Partici-
pants were randomised to receive either placebo or 160 mg/
kg/day genistein aglycone for 12 months. All participants
subsequently received 160 mg/kg/day genistein aglycone
for a further 12 months. The primary outcome measure
was HS concentration in cerebrospinal fluid (CSF) at
12 months. Secondary outcome measures were: CSF and
plasma genistein levels, urine and plasma HS, total urinary
GAG, neuropsychological assessments, actigraphy, care-
giver mood, and quality of life measures. Safety assessments
included physical examinations (including pubertal stag-
ing), adverse event (AEs) recording, six-monthly monitor-
ing of haematological and biochemical parameters in blood
(including hepatic profile, thyroid function tests, gonadotro-
pin levels and sex hormones), and six-monthly ultrasound
examination of the pelvis in female participants.
2.3 | Participants
Inclusion criteria were: (a) aged between 2 and 15 years
(inclusive) at the time of consent; (b) confirmed diagnosis
of MPS IIIA, B or C by enzyme assay in leukocytes or
fibroblasts, and/or presence of known pathogenic muta-
tions in SGSH, NAGLU or HGSNAT; (c) clinical signs
and symptoms of MPS III; (d) able to walk unaided.
Exclusion criteria were: (a) previous haematopoietic stem
cell transplantation; (b) use of genistein or any other
investigational therapy for MPS III; (c) known adverse
reaction to genistein; (d) pregnancy; (e) clinically signifi-
cant symptoms unrelated to MPS III that would influence
results in the opinion of the investigators.
2.4 | Sample size calculation
An indirect sample size estimate was made on the basis of
uGAG reduction observed in a previous placebo-controlled
crossover study of genistein.25 As a much higher dose of
genistein was used in this study, a difference of twice that
seen in the de Ruijter et al study was targeted. A sample
size of 24 participants was estimated to have 90% power to
detect such a difference. A total of 21 participants were
recruited; 20 completed the placebo-controlled phase and
were included in the analysis (Figure 1).
2.5 | Early termination of study
The study was terminated in June 2018 due to shelf-life
expiry of the genistein aglycone product. All active partic-
ipants attended 24-month study visits prior to study ter-
mination. CSF samples were not obtained for two
participants due to logistical difficulties, but all other
study procedures were completed.
2.6 | Interventions
Genistein aglycone powder (BONISTEIN) was manufactured
and tested according to good manufacturing practice (GMP)
standards by DSM Nutritional Products Ltd and was re-
packaged into 250 g (210 mm  135 mm) laminated foil
pouches by Quay Pharmaceuticals, also at GMP standard.
Matching placebo product (Maize starch 99.7/quinolone yel-
low 0.3%) was manufactured by Quay pharmaceuticals and
packaged in identical pouches. A stability testing programme
was implemented according to ICH stability guidelines,
6 months following re-packaging of the Genistein, and annu-
ally thereafter for the duration of the trial. These tests were
performed by DSM Nutritional products Ltd and CoAs
issued to comply with GCP and GMP. Blind testing was
implemented to ensure matching of placebo and drug.
The dose of genistein aglycone for each individual was
converted into a specified number of standardised scoops
(1.25 mL or 2.5 mL) of powder. A scoop validation study was
performed with caregivers (n= 4) to assess accuracy of dosing
with a maximum variation (95% CI) of 1.95% to +13.9% for
a target dose of 3.0 g (6  1.25 mL scoops) and 95% CI of
+4.0% to+8.5% for a target dose of 6.0 g (6  2.5 mL scoops).
95% of measurements were within 13.5% tolerance for the
1.25 mL scoop and 95% within 8.5% tolerance of the expected
dose for the 2.5 mL scoop. Caregivers were instructed to give
a specified number of scoops of powder, and instructions
were updated at each study visit based on participant weight.
Details of frequency of missed doses were recorded at each
study visit to estimate compliance.
2.7 | Randomisation
Participants were randomised in a 1:1 ratio to receive
genistein or placebo, stratified by MPS subtype (MPS IIIC
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vs MPS IIIA or IIIB) and with allocation in blocks of ran-
dom size. Randomisation was performed using an online
randomisation tool (www.randomisation.com). All par-
ticipants, caregivers, intervention providers, investigators
and statisticians remained blinded until the end of the
placebo-controlled phase, following which the allocation
list was revealed to investigators.
2.8 | Outcome measures
2.8.1 | Biochemical outcome measures
HS concentrations in CSF, plasma and urine were mea-
sured at Amsterdam UMC using previously described
methods.27-29 In short, samples were prepared by
heparinase digest and resultant disaccharides were quan-
titated by UPLC-MS/MS. Total HS was calculated as the
sum of D0A0, D0S0, D0A6 + D2A0, and D0S6 + D2S0
disaccharides. Urine HS measurements were corrected
for creatinine concentration. Urinary GAG concentra-
tions were measured using the dimethylmethylene blue
(DMB) assay30 at the Willink Biochemical Genetics Unit,
Manchester.
2.8.2 | Neuropsychological evaluations
Neuropsychological evaluations were performed by spe-
cialist paediatric neuropsychologists with substantial
experience of assessing children with MPSIII. Cognitive
assessment was performed using age-appropriate tests:
for most participants, the Bayley Scales of Infant and
Toddler Development, Third Edition (BSID-III) were
used. The Stanford-Binet Intelligence Scales, Fifth Edi-
tion was used in one participant. Adaptive behaviour was
assessed using the Vineland Adaptive Behaviour Scale—
Survey Interview Form, Second Edition (VABS-II). Scores
are expressed as age equivalent scores (AgeEqSs) and
developmental quotients (DQs), where DQ = (age equiv-
alent/chronological age)  100.
2.8.3 | Caregiver mood and quality of life
measures
Caregivers completed the Beck Depression Inventory
(BDI-II), a self-report inventory for measuring the sever-
ity of depression. Scores range from 0 to 63 and defined
as: 0 to 13, minimal depression; 14 to 19, mild depression;
FIGURE 1 GENiSIS2013
participant flow. One participant
was randomised and completed
baseline assessments but
discontinued due to logistical
difficulties and did not return for
any further study visits. One
participant withdrew at
14 months due to adverse
effects. *Two participants,
originally allocated to placebo,
remained active at the point of
study termination, but all
24-month study procedures
other than CSF sample
collection had been completed
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20 to 28, moderate depression; 29 to 63, severe depres-
sion. Caregivers also completed the parent report Paediat-
ric Quality of Life Inventory (PedsQL) (caregiver
estimates of the quality of life of children) and PedsQL
family impact module (caregiver estimates of quality of
life of the family). Both are expressed as percentages,
where 100% is no impact on quality of life, and 0% is
severe impact on quality of life.
2.8.4 | Actigraphy
Participants wore Respironics Actiwatch 2 actigraphs
(Philips Respironics, Bend, Oregon) on their non-
dominant wrist continuously for 5 to 10 days, with data
sampling across 15-seconds epochs.
Only participants for whom there were a minimum of
5 days continuous actigraphy recordings were included
in the analysis: 13 at baseline (6 placebo, 7 genistein) and
12 at 12 months (7 placebo, 5 genistein).
Data was downloaded and analysed using El
Temps (A. Diez-Noguera, University of Barcelona, Bar-
celona, Spain), following the procedures described
previously,31,32 Parametric and non-parametric tests
were applied to characterise activity rhythms. The
parametric tests used were the χ2-periodogram,33
cosinor analysis and Rayleigh test,34 from which the
following values were calculated: period of the rhythm,
percentage of variance, cosinor, mesor, cosinor
acrophase, cosinor amplitude and r vector length. In
addition, using the mean waveform, the proportion of
daytime activity in relation to the overall daily activity
levels (%) was calculated, together with M10 activity
levels, M10 duration, L5 activity levels and L5 duration
(see Mumford et al for further details). The following
non-parametric variables were also calculated31,32:
interdaily stability (IS), intradaily variability (IV) and
relative amplitude (RA).
2.8.5 | Measurement of cytokines in CSF
and plasma
Concentrations of cytokines in in control and MPS III
human plasma and CSF were evaluated using a commer-
cially available Bio-Plex ProTM Human Cytokine 27-Plex
Assay (Bio-Rad Laboratories Ltd., Watford, UK) mea-
sured with a Bio-Plex 200 system (Bio-Rad Laboratories
Ltd.) powered by Luminex xMAP technology (Luminex,
Austin, Texas), as described by Parker et al.35 Control
samples were from healthy adults (plasma) or commer-
cially available single donor CSF (Lee Biosolutions, Cata-
logue number 991-19-S).
2.9 | Statistical analysis
For CSF, plasma and urine HS, and urine GAG,
analysis of covariance (ANCOVA) was used to compare
genistein and placebo groups at 12 months, controlling
for baseline value and for stratification variable (C vs
non-C subtype). HS and GAG concentrations were log-
transformed prior to analysis. Untransformed BSID-III
and VABS-II DQ scores were analysed by ANCOVA, con-
trolling for age at baseline, baseline DQ and MPS sub-
type. Untransformed BDI-II and PedsQL scores were
analysed by ANCOVA controlling for baseline value and
MPS subtype. Significance was set at 5%. Where log-
transformed values were used, results are expressed as %
difference between genistein and placebo after 12 months
(adjusted for baseline). Analysis was performed using
GraphPad Prism 7 software (La Jolla, California) and
SPSS statistics v.24 (IBM, Armonk, New York).
Actigraphic data were analysed by ANOVA of general
linear models using SPSS statistics v.22 (IBM, Armonk,
New York). For all models, independent variables were
treatment (placebo or genistein), experimental stage
(baseline or 12 months) and interaction between these
two variables.
Cytokine concentrations in genistein, placebo and
control groups were analysed using one-way ANOVA,
followed by Tukey's multiple comparisons test.
3 | RESULTS
3.1 | Baseline characteristics, safety and
tolerability
Baseline characteristics are summarised in Table 1. Three
of the four participants with MPS IIIC were randomised
to the placebo group. Genistein was generally well toler-
ated by participants, with only one adverse event consid-
ered to be clearly related to genistein (Table S1). This was
the development of Tanner stage II breast tissue in three
male participants (aged 4.3, 7.9 and 7.6 years) that was
not present at baseline. One participant who was initially
allocated to the placebo group withdrew from the study
shortly after commencing the open-label phase, due to
reported decreasing responsiveness. Though no other
patient reported similar symptoms, a relationship with
genistein could not be completely excluded. Two male
participants developed elevated testosterone levels during
the study, one of whom had elevated gonadotropin levels
and evidence of progression into puberty at 9.5 years of
age. One female participant developed biochemical and
clinical evidence of progression into puberty at 9.1 years
of age. All participants were found incidentally to have
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highly elevated sex hormone binding globulin (SHBG) at
baseline (range 153-653 nmol/L). Six participants had ele-
vated alanine transaminase (ALT) at baseline which did
not deteriorate during the study (maximum 1.2-2.1 x
upper limit of normal, ULN). A total of four participants
across both genistein and placebo groups developed ele-
vated ALT during the course of the study (maximum
1.2-2.3  ULN. Five participants across both genistein
and placebo groups developed elevated thyroid stimulat-
ing hormone during the study, one of whom had previ-
ously been treated for hypothyroidism.
3.2 | Treatment with 160 mg/kg/day
genistein aglycone led to plasma and CSF
genistein concentrations consistent with
previous clinical and pre-clinical studies
Genistein aglycone at a dose of 160 mg/kg/day was deliv-
ered as two oral doses every 24 hours (0 hour,12 hours,
24 hours, 36 hours). The pharmacokinetic profile was
assessed in all participants over a 12-hour period follow-
ing their first dose and third doses of genistein
(Figure 2A). Genistein is rapidly glucuronidated, or oth-
erwise modified in humans, which significantly reduces
activity.36 Thus, the peak plasma concentration of free
and fully active genistein (genistein aglycone) in partici-
pants receiving genistein was measured as 339 ng/mL at
4 hours after the first dose and 508 ng/mL at 2 hours
after the third dose. Plasma genistein concentrations
were also measured at 12 months and 24 months
(Figure 2B): mean plasma free genistein (in genistein
group participants) was 84 ng/mL at 12 months (95% CI
27-142 ng/mL), and at 36 ng/mL at 24 months (95% CI
12-60 ng/mL). In participants originally on placebo,
mean plasma free genistein concentrations were 87 ng/
mL at 24 months (ie, after 12 months of genistein), 95%
CI 22-153 ng/mL). Plasma free genistein concentrations
were also measured in samples from previous clinical
studies of genistein25,26 (Figure 2C). A dose of 10 mg/kg/
day soy-derived genistein from the 30 patients on the
Dutch trial25 was associated with mean plasma free
genistein concentration of 13 ng/mL (95% CI
5.9-20.1 ng/mL), whereas a dose of 100 mg/kg/day from
the US trial26 was associated with mean plasma free
genistein of 90 ng/mL (12.3-193 ng/mL). The plasma
concentrations of genistein observed in the GENiSIS2013
trial are comparable to previous studies. Mean CSF con-
centrations of free genistein were 4.9 ng/mL in the genis-
tein group at 12 months (95% CI 2.0-7.8 ng/mL);
4.9 ng/mL at 24 months (95% CI 2.7-7.2 ng/mL), and in
participants initially in the placebo group, mean CSF free
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(95% CI 0.6-3.4 ng/mL) (Figure 2D). CSF concentrations
were approximately 2% to 13% of plasma concentrations,
consistent with pre-clinical studies.37
3.3 | Treatment with 160 mg/kg/day
genistein aglycone was not associated with
significant reductions in CSF HS, plasma
HS or urine HS, but there was a significant
reduction in urine GAG
Patients were randomised to placebo or genistein for
12 months, following which all patients received genis-
tein (Figure 3A). From baseline to 12 months, CSF HS
decreased in the genistein group but increased in the pla-
cebo group. However, CSF HS increased in both groups
from 12 months to 24 months, when all participants were
receiving genistein (Figure 3B). The difference in CSF HS
between genistein and placebo groups after 12 months
was not statistically significant in the ANCOVA analysis
(estimated difference: 5.5% lower in genistein group, 95%
CI: 14.7% lower to 4.7% higher, P = .260) (Figure 3C).
Thus, the study did not meet its primary endpoint of a
reduction in CSF HS from baseline to 12 months. Mean
concentrations of plasma HS, urine HS and urine GAG
decreased in both groups over time (Figure 3D,E,F).
There was a statistically significant change in plasma HS
concentration from baseline to 12 months (P = .021) and
from baseline to 24 months in the genistein group
(P = .027), but not in the placebo group (Table S2). How-
ever, this was not statistically significant in the ANCOVA
analysis (estimated difference at 12 months: 10.4% lower
in genistein group, 95% CI: 23.4% lower to 4.9% higher,
P = .159). Similarly, the estimated difference in urine HS
between genistein and placebo after 12 months of treat-
ment was not statistically significant (5.1% lower in genis-
tein group, 95% CI: 30.8% lower to 30.0% higher, P = .73).
The only biochemical outcome measure for which there
was a significant difference between groups in ANCOVA
analysis was urinary GAG at 12 months (32.1% lower in
the genistein, 95% CI: 53.8% lower to 0.1% lower,
P = .0495). However, urinary GAG concentrations
FIGURE 2 Pharmacokinetic profile of genistein and plasma/CSF genistein concentrations. Data shown are means with 95% CI. A,
Pharmacokinetic profile of genistein after dosing at 0 hour, 12 hours, 24 hours, 36 hours. Blue arrows denote timing of genistein doses. B,
Genistein concentration in plasma in participants in this study at baseline, 12 months and 24 months. C, Genistein concentrations in plasma
in participants from de Ruijter et al25 and Kim et al26 studies. D, Genistein concentrations in CSF in participants in this study at baseline,
12 months and 24 months
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remained well above the normal range in both groups
(Figure 3F).
3.4 | No differences in
neuropsychological or quality of life
measures were observed between placebo
and genistein groups
The developmental trajectory of MPS IIIA, IIIB and IIIC
individuals in both genistein and placebo groups closely
followed the curves of published natural history data for
MPSIIIA38 throughout the 24 months of the study. This
included a small subset of individuals from both MPS
IIIC and non-C subtypes who followed more attenuated
courses (Figure 4A,B). The decline in DQ over the first
12 months was greater in the placebo group (mean
decline of 9.6 points) than in the genistein group
(mean decline of 3.2 points) (Table S3). However, many
individuals in the genistein group had low baseline DQ,
and clustered near the “floor” of the test, whereas there
were several younger individuals in the placebo group
with higher baseline DQ. Age at baseline was therefore
controlled for in the analysis, and the difference between
groups at 12 months was small and not statistically sig-
nificant (1.4 points higher in the genistein group, 95% CI
1.7 points lower to 4.6 points higher, P = .347).
Results for adaptive behaviour followed a similar pat-
tern (Figure 4C,D). There was no statistically significant
difference between genistein and placebo groups at
12 months (mean difference 0.3 points lower in the genis-
tein group, 95%CI 4.1 points lower to 4.8 points higher,
P = .868) (Table S2).
Caregiver mood was assessed using the BDI-II. At
baseline, mean BDI-II scores in the genistein group ranged
from minimal to moderate depression and from minimal
to severe depression in the placebo group (Table S3). The
BDI-II score for a parent of one participant in the placebo
group increased from 20 at baseline to 46 at 12 months,
prompting a referral to primary care services for further
assessment. Mean changes in scores during the course of
the study were small (Figure 4E). The difference between
groups at 12 months, adjusted for baseline, was small and
not statistically significant (3.9 points lower in the genis-
tein group, 95% CI: 13.3 points lower to 5.5 points higher)
(Table S3). Parents Paediatric Quality of Life Question-
naires (PedsQL) and PedsQL Family Impact module scores
at baseline indicated significant impact on the parents'
FIGURE 3 Biochemical outcome measures. A, GENiSIS2013 study design. B, CSF HS concentrations at baseline, 12 months and
24 months. C, Comparisons by ANCOVA, given as % difference between genistein and placebo groups at 12 months, adjusted for baseline
values. D, Plasma HS concentrations at baseline, 12 months and 24 months. E, Urinary HS concentrations at baseline, 12 months and
24 months. F, Urinary GAG concentrations at baseline, 12 months and 24 months. Data shown are means with 95% confidence intervals.
Circles with dashed connecting line = genistein; squares with solid connecting line = placebo; squares with dotted connecting
line = placebo group changed to genistein during extension phase. Dashed- dotted line in panel (F) represents upper limit of normal for
youngest participant at baseline. *P < .05. CSF, cerebrospinal fluid; GAG, glycosaminoglycan; HS, heparan sulfate
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FIGURE 4 Neuropsychological outcome measures and quality of life measures. A, Bayley age equivalent scores by chronological age,
with MPS IIIA natural history. B, Bayley DQ by chronological age, with MPS IIIA natural history. C, Vineland age equivalent scores by
chronological age. D, Vineland DQ by chronological age. E, Beck Depression Inventory scores (0–13 = minimal depression; 14–19 mild
depression; 20–28 = moderate depression; 29–63 = severe depression). F, Parents PedsQL scores, given as percentages, where 100% = no
impact on quality of life of child and 0% = severe impact on quality of life of child. G, PedsQL Family Impact Inventory, given as
percentages, where 100% = no impact on quality of life of family and 0% = severe impact on quality of life of family. For panels (A-D), data
shown are individual participants. For panels (E-G), data shown are means with 95% confidence intervals. DQ = [age equivalent score/
chronological age]  100. Circles with dashed connecting line = genistein; squares with solid connecting line = placebo; squares with dotted
connecting line = placebo group changed to genistein during extension phase; open circles = MPS IIIC participants randomised to genistein;
open squares = MPS IIIC participants randomised to placebo and changed to genistein during extension phase; triangles = Stanford-Binet
scores for one MPS IIIA participant who scored above the limits of Bayley scales; grey lines without symbols = MPS IIIA natural history data
from Shapiro et al38; grey dashed lines without symbols = MPS IIIA “slow progressors” from Shapiro et al.38 Solid lines in panels (A) and
(C) represent trajectory of normal development. Bayley, Bayley Scales of Infant and Toddler Development, Third Edition; DQ, developmental
quotient; Vineland, Vineland Adaptive Behaviour Scales, Second Edition
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perceived quality of life of their child and the parents'
reported quality of life of the family (Table S3). From base-
line to 12 months, the Parents PedsQL scores improved in
the genistein group and deteriorated in the placebo group
(Figure 4F), and approached statistical significance (10.0
percentage points higher in the genistein group, 95% CI:
0.6 percentage points lower to 20.6 percentage points
higher, P = .061) (Table S3). However, scores deteriorated
in both groups from 12 months to 24 months (Figure 4F).
Family Impact scores improved by a greater degree in the
genistein group from baseline to 12 months, though this
was not statistically significant, and again, scores deterio-
rated in both groups from 12 months to 24 months.
3.5 | No statistically significant changes
in actigraphic outcome measures were
observed between genistein and placebo
groups
Several actigraphic variables differed between treatment
groups, though this was at both baseline and 12-month
time points. Across both timepoints, the genistein group
showed higher levels of daytime activity (94.3 ± 2.4%)
than the placebo group (91.2 ± 3.5%) (P < .05, data not
shown). Similarly, across both timepoints, cosinor ampli-
tude, which indicates strength of the rhythm, was signifi-
cantly higher in the genistein group (4394 ± 1904)
compared to the placebo group (3232 ± 1630) (P < .05).
Intradaily variability (IV), which gives an indication of
the level of fragmentation of the rhythm, was also signifi-
cantly higher in the genistein group (0.70 ± 0.18) than in
the placebo group (0.53 ± 0.17) (P < .05). However, there
was no statistically significant interaction between treat-
ment group and timepoint, suggesting that there was no
independent treatment effect of genistein.
The period of the activity rhythm was shorter at base-
line (23.8 ± 0.3 hour) compared to the 12-month time-
point (24.1 ± 0.2 hour), but this was across both
treatment groups (P < .05). No other significant interac-
tion between treatment group and timepoint was found.
3.6 | Cytokines
Significant elevations in certain cytokines (including IL-
1β, IL1RA,35 MCP-1, MIP-1α and MIP-1β) were seen in
participants over unaffected individuals, but there were
no significant differences in the change from baseline to
12 months for any cytokine as a result of genistein treat-
ment (data not shown). Patients in the genistein group
generally had higher baseline cytokine levels than those
in the placebo group which confounded analysis.
4 | DISCUSSION
This is the first double-blinded, placebo-controlled clini-
cal trial of high dose genistein aglycone in patients with
MPSIII that was designed to specifically address whether
high dose genistein improves neurological disease symp-
toms. We show here that although we could demonstrate
that significant amounts of genistein were present in the
blood circulation as a result of dosing, and despite being
able to demonstrate a small but significant reduction in
urinary GAGs, we did not demonstrate any effect on neu-
rocognition, psychological well-being of individuals or
families, or other clinical symptoms including inflamma-
tory cytokine levels or actigraphy.
Initial open label clinical studies of genistein deliv-
ered as SOYFEM (a standardised soy isoflavone extract)
in patients at doses of between 5 and 10 mg/kg/day genis-
tein aglycone were inconclusive, with one delivering
5 mg/kg/day suggesting small improvements in
10 patients,22,23 whilst similar studies in Spain24
in 19 Sanfilippo patients, suggested no clinical effect. A
previous placebo-controlled study using doses of
10 mg/kg/day Soyfem demonstrated a significant reduc-
tion of urinary GAGs,25 as we showed here, but they too
were unable to show clinical improvements or
stabilisation in neurocognitive tests. A later study in the
US using very high doses of genistein aglycone 60 to
150 mg/kg/day26 was not set up to monitor clinical out-
comes. As we demonstrate here, the patients from the de
Ruijter study had an average circulating genistein level of
13 ng/mL, (Figure 2C) whereas with a dose 16-fold
higher, we achieve between 339 and 508 ng/mL at cMax
from our PK data (Figure 2A) and 36 to 87 ng/mL steady
state levels in our long-term measurements (Figure 2B,
D), suggesting that we should have seen a larger effect
size on GAG or HS reduction. Sporadic measurements
from patients on the US study receiving 60 mg/kg or
100 mg/kg genistein aglycone were consistent with this
observation (Figure 2C).
CSF bioavailability of genistein aglycone was slightly
lower than expected (between 2% and 13% of input),
although not inconsistent with previous reports of 10%
bioavailability in the brains of rats19 and our own data in
mice (data not shown) of 8.5% brain bioavailability. It is
possible that the genistein aglycone levels achieved in the
brain in this study (2-5 ng/mL) remained too low to
achieve a biochemical effect and this was borne out by a
lack of significant changes in CSF HS or in neuro-
cognition in the treated group. Some clues may be seen
from a dose finding study in male MPSIIIB mice20 that
show initial dose dependent decreases in liver GAGs
between 0-15 mg/kg/day, and no further decreases
between 15-160 mg/kg/day, suggesting that genistein
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may have an L-shaped dose response curve on GAG
reduction. In contrast, a long-term double-blinded study
of high dose genistein aglycone demonstrated a consis-
tent 37% reduction of HS in the brain of MPSIIIB mice,
suggesting that bioavailability could be an issue. None-
theless, we found plasma and brain bioavailability of the
active unconjugated “free” form of genistein (genistein
aglycone) to be very similar between mice and humans,
although plasma levels of the less active conjugated
genistein form were much higher in humans due to
higher glucuronidation and sulphation rates of
oestrogenic compounds such as genistein in humans. The
data therefore suggested that there should have been suf-
ficient bioavailability of genistein aglycone in both
plasma and the CSF to achieve GAG reductions. The
hypothesis that reduction of heparan sulphate in
Sanfilippo could impact positively on disease status is still
very much viable, and can be demonstrated in several
preclinical models using siRNA, shRNA or genetic
models designed to reduce HS synthesis39-41. Genistein
however, does not produce a significant enough effect
size to impact on pathology in humans.
Higher dosing of genistein would not be rec-
ommended, as the NOAEL for chronic dosing is under
500 mg/kg/day in rodents42 and 500 mg/kg/day in dogs.43
Indeed, Kingma and colleagues recently described
adverse effects of genistein in mouse models of the
related GAG storage disease MPS I, including decreased
femur and body length and 60% of mice with scrotal her-
nia.44 In the study by Kim and colleagues of participants
receiving 150 mg/kg/day genistein aglycone, two boys
developed Tanner stage II breast development and two
female participants developed menstrual irregularities
during the course of the study.26 In comparison, three
boys developed Tanner stage II breast development in
this study. Similarly, we observed moderate elevations
in alanine transaminase in four participants that did not
exceed three times the upper limit of normal, as was
described in three participants in the study by Kim and
colleagues.26 In conclusion, we found that genistein is
safe and well tolerated in MPSIII patients.
We compared our age equivalent cognitive scores to a
natural history study of 20 MPSIIIA patients published
by Shapiro and colleagues.38 Although we had a mixture
of MPS IIIA, MPS IIIB and MPS IIIC patients on this
trial, and despite some obvious differences in course of
disease for some patients who had an attenuated pheno-
type, it was clear that there were no changes to overall
rate of decline between placebo or genistein groups as
measured for either age equivalent DQ or adaptive
behaviour. We observed attenuated phenotypes in two
patients with MPS IIIA (Table 1, subjects #1 and #15)
and one patient with MPS IIIB (Table 1, subject #16).
Subject #1 was compound heterozygous for p.
(Ser298Pro), a variant known to be associated with slowly
progressing MPS IIIA,3,45 and c.1027dupC, which has
previously been observed in a homozygous state in rap-
idly progressing individuals.46,47 Subject #15 was com-
pound heterozygous for p.(Gly191Arg), a variant which
has previously observed in trans with other variants in
individuals with rapidly progressing MPS IIIA,45,48 and a
novel variant, p.(Cys183Tyr). Subject #16 was homozy-
gous for a novel in-frame deletion in NAGLU. Overall
baseline HS values did not appear to be different for dif-
ferent rates of progression or subtype suggesting that HS
levels are not prognostic at baseline for severity of dis-
ease. A slower clinical course of disease has been well
documented for MPS IIIC,4,5 and our findings were con-
sistent with this.
This study recruited participants from a broad age
range, with the youngest participant being 38 months old
at baseline. Participants under 2 years of age were not
recruited as such children would potentially have been
eligible for participation in the increasing number of gene
therapy clinical trials that were becoming available dur-
ing this period. However, the heterogeneity of the partici-
pants is a limitation of the study. In addition, many of
the participants already had marked impairment on neu-
ropsychological assessments at baseline, limiting the
potential of the study to identify differences in cognitive
outcomes. For this reason, a biochemical outcome mea-
sure (CSF HS) was chosen as the primary endpoint.
The difficulty of using CSF HS reductions as a clinical
surrogate for brain HS or even a predictor of
neurocognitive outcomes in MPSIII have previously been
highlighted by us49 and others.50 Gene therapy studies in
MPS IIIA7 and MPSIIIB51 have further brought this into
context, where significant reductions in CSF HS have been
seen without consequential changes in neurocognitive out-
comes. Given the difficulties of achieving neurocognitive
changes in this population with an enzyme replacement
gene therapy, and the suggestion that reductions of 50% to
70% of brain HS may be needed to achieve this from our
own preclinical gene therapy studies in MPS IIIA, MPS
IIIB and MPS IIIC,52-54 it seems unlikely that any substrate
reduction therapy product could reduce GAG sufficiently
to achieve improvements in neurocognition in MPS III.
Miglustat is approved as a substrate reduction therapy for
Gaucher disease, however, it has a dual function as a
chaperone and has a much more specific action on its sub-
strate than genistein. As such, any future SRTs should be
more specifically targeted and may need to be able to
reduce GAG by over 50% in the brain in order to stand a
chance of clinical success.
Despite seeing small but significant reductions in the
preclinical mouse study of high dose genistein in
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MPSIIIB mice,21 we were unable to show any significant
reductions in a panel of elevated cytokines in MPS III
patients. These data further suggest that the effect size of
genistein in humans was lower than expected and sug-
gest that although the product has sufficient bioavailabil-
ity, it is unable to reduce GAGs or reduce
neuroinflammation sufficiently to mediate any detectable
changes in patients. Preclinical data from our laboratory
has suggested that behaviour in MPSIIIA35,52 can be
influenced by reduction of inflammation in the absence
of storage reduction. As genistein has multiple effects,
including a small but significant reduction in brain
inflammation in MPSIIIB mice,21 this, coupled with mod-
est GAG reductions may also help to explain why it was
ineffectual in patients.
In conclusion, our data strongly suggest that despite
sufficient bioavailability of high dose genistein aglycone
in patients receiving the drug for up to a 2-year period,
there is no clinical benefit to be seen for neurological and
neurocognitive signs and symptoms of MPS III. In addi-
tion, biochemical somatic benefits were marginal at best,
and similar effects could be achieved with much lower
doses of genistein in Soyfem form. As such, we do not
recommend the use of genistein aglycone at any dose for
the treatment of MPS III or other similar neurological
diseases storing glycosaminoglycans.
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